Magnetic Seizure Therapy for Schizophrenia - Trial

NANot yet recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

November 30, 2028

Study Completion Date

November 30, 2028

Conditions
Treatment Resistant SchizophreniaSchizophreniaSchizoaffective Disorder
Interventions
DEVICE

Magnetic Seizure Therapy (MST)

MST treatment will be administered using the MagPro MST with a Cool TwinCoil over the frontal cortex in the midline position using 100 Hz stimulation at 100% machine output. Seizure threshold will follow prior protocols used for frontal MST. Patients will receive care and be managed by anaesthesia as per standard ECT practice.

DEVICE

Electroconvulsive Therapy (ECT)

In the ECT arm treatment, the MECTA spectrum 5000Q or MECTA sigma machine will be used. The ECT determination of seizure threshold and the adjustment of energy at subsequent sessions will be based on a standard published protocol. All participants will receive RUL-UB ECT at six times the seizure threshold. Patients will receive care and be managed by anaesthesia as per standard ECT practice.

Trial Locations (2)

V6T 2A1

University of British Columbia Hospital, Vancouver

M6J 1H4

Centre for Addiction and Mental Health, Toronto

All Listed Sponsors
collaborator

University of British Columbia

OTHER

lead

Centre for Addiction and Mental Health

OTHER

NCT06672588 - Magnetic Seizure Therapy for Schizophrenia - Trial | Biotech Hunter | Biotech Hunter